What drug classes act on HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase?

Drug classes acting on HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase include Direct-acting antiviral (DAA) combination, Direct-acting antiviral combination (NS5A inhibitor + nucleotide polymerase inhibitor).

HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase — Drug Target

6 drugs 6 marketed

All drugs that target HCV NS5A protein and HCV NS5B RNA-dependent RNA polymerase — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

Direct-acting antiviral (DAA) combination · Direct-acting antiviral combination (NS5A inhibitor + nucleotide polymerase inhibitor)

Marketed (6)

Daclatasvir + Sofosbuvir · Federal University of São Paulo · Direct-acting antiviral (DAA) combination · Virology / Hepatology
Daclatasvir and sofosbuvir work together to inhibit hepatitis C virus (HCV) replication by blocking the NS5A protein and the NS5B RNA polymerase, respectively.
Ledipasvir and sofosbuvir · National Taiwan University Hospital · Direct-acting antiviral combination (NS5A inhibitor + nucleotide polymerase inhibitor) · Infectious Disease / Virology
Ledipasvir inhibits hepatitis C virus NS5A protein and sofosbuvir inhibits NS5B polymerase, together blocking viral replication.
Ledipasvir/Sofosbuvir · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · Direct-acting antiviral combination (NS5A inhibitor + nucleotide polymerase inhibitor) · Virology / Hepatology
Ledipasvir inhibits hepatitis C virus NS5A protein while sofosbuvir inhibits the viral NS5B polymerase, together blocking HCV replication.
D+Z · Sequential Medicine Ltd · Direct-acting antiviral (DAA) combination · Virology / Hepatology
D+Z is a fixed-dose combination of daclatasvir and sofosbuvir that inhibits hepatitis C virus NS5A and NS5B proteins to block viral replication.
Combined therapy LDV and SOF · Yassin Abdelghaffar Charity Center for Liver Disease and Research · Direct-acting antiviral combination (NS5A inhibitor + nucleotide polymerase inhibitor) · Virology / Hepatology
LDV (ledipasvir) and SOF (sofosbuvir) are direct-acting antivirals that inhibit hepatitis C virus NS5A and NS5B polymerase, respectively, blocking viral replication.
Daclinza and Sunvepra · Pusan National University Hospital · Direct-acting antiviral (DAA) combination · Virology / Hepatology
Daclatasvir and sofosbuvir are direct-acting antivirals that inhibit hepatitis C virus NS5A and NS5B polymerase proteins, respectively, to block viral replication.